LTR Pharma Shares Surge On Positive Clinical Study Results For SPONTAN

LTR Pharma Ltd (ASX: LTP) shares surged more than 30% intra-day after revealing positive initial results from its pivotal bioequivalence clinical study of SPONTAN nasal spray treatment of Erectile Dysfunction (ED).

Initial data from the study shows that SPONTAN reached the same Cmax (maximum concentration) level as an oral administration, despite being administered at a lower dose.

This was achieved in as little as 9 minutes with an average of 12 minutes across the study compared to 56 minutes in patients receiving oral treatment.

Improved safety and tolerance

Importantly, SPONTAN also demonstrated an improved safety and tolerance profile, providing reassurance and confidence in its use.

The study also showed better consistency in response for the nasal spray patient cohort, thus achieving both primary and secondary endpoints.

Effective solution for erectile dysfunction

LTR Pharma Chairman Lee Rodne said: “The initial results from our pivotal clinical study are encouraging. SPONTAN has the potential to make a significant impact on the global PDE5 inhibitor market, providing men with a more convenient and effective solution for erectile dysfunction (ED).

 “This Study further underscores the rapid onset of action of SPONTAN and represents a significant advancement over existing gold-standard oral therapies, which can take over an hour to take effect.

 “This milestone brings us closer to our mission of enhancing men’s health and quality of life.”

Set apart from existing ED therapies

ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets.

LTR Pharma’s lead product, SPONTAN, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor.

The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within a few minutes.

As at 31 March 2024, LTR Pharma held cash of A$5.28 million, strongly positioning it to meet its upcoming milestones.



JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest